Source: Arch Internal Med
Area: News
This retrospective study, using The Health Improvement Network (THIN) database, evaluated the short and long-term risks of developing diabetic macular oedema (DMO) among patients with type 2 diabetes who were treated with thiazolidinediones (rosiglitazone and pioglitazone).
Researchers identified adult patients with type 2 diabetes (not requiring insulin therapy within 6 months of diagnosis), were 18 years or older, and were registered with the medical practices for at least one year from the index date of January 2000. The THIN database also determined the (Read more...)
Uncategorized